![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif)
(PAH-lee-EH-thih-leen gly-KAH-sih-lay-ted ree-KOM-bih-nunt HYOO-mun MEH-guh-KAH-ree-oh-site …)
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif)
| A form of megakaryocyte growth and development factor (MGDF) that is made in the laboratory. MGDF comes from the protein thrombopoietin, which is normally made in the body to help make platelets. Polyethylene glycosylated recombinant human megakaryocyte growth and development factor is being studied as a way to increase the number of platelets in patients receiving chemotherapy. Also called PEG-MGDF and PEG-rhMGDF. |
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090115175105im_/http://www.cancer.gov/images/spacer.gif) |